Clarifying the romosozumab “Super-Responder” phenotype: response to methodological concerns
Osteoporosis International · 2026-10 · 37 (10) · 2779-2780
DOI: 10.1007/s00198-026-08130-2 ↗Kurz gefasst
Leserbrief in der Zeitschrift Osteoporosis International, online erschienen am 06.07.2026. Verfasst von Alberto Ghielmetti und 2 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Endocrinology and Metabolism, University Hospital Santa Maria Della Misericordia, 33100, Udine, Italy. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Unit of Endocrinology and Metabolism, University Hospital Santa Maria Della Misericordia, 33100, Udine, Italy.
- Endocrine Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, 20122, Milan, Italy.
- Endocrine Unit, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, 20122, Milan, Italy. cristina.eller@policlinico.mi.it.
Zitieren
APA
Ghielmetti, A., Grassi, G., & Eller-Vainicher, C. (2026). Clarifying the romosozumab “Super-Responder” phenotype: response to methodological concerns. Osteoporosis International, 37(10), 2779-2780. https://doi.org/10.1007/s00198-026-08130-2
Vancouver
Ghielmetti A, Grassi G, Eller-Vainicher C. Clarifying the romosozumab “Super-Responder” phenotype: response to methodological concerns. Osteoporosis International. 2026;37(10):2779-2780. doi:10.1007/s00198-026-08130-2
BibTeX
@article{Ghielmetti2026,
author = {Ghielmetti, Alberto and Grassi, Giorgia and Eller-Vainicher, Cristina},
title = {Clarifying the romosozumab “Super-Responder” phenotype: response to methodological concerns},
journal = {Osteoporosis International},
year = {2026},
volume = {37},
number = {10},
pages = {2779--2780},
doi = {10.1007/s00198-026-08130-2}
}
EUVIMED